
Buy Now or Pay More Later? ‘Macroeconomic Uncertainty' Has Shoppers Anxious
Buying something before you absolutely need it isn't always affordable. But if there were ever a time to consider making an early investment, this would be it. President Donald Trump's tariffs are beginning to nudge prices higher on products from high-end strollers to cheap smartphone chargers.
This is an essay from the latest edition of Steven Levy's Plaintext newsletter.
SIGN UP for Plaintext to read the whole thing, and tap Steven's unique insights and unmatched contacts for the long view on tech.
The Trump administration has suggested the tariffs are a negotiating tactic. Some could be eliminated as the US makes deals with other countries. That means US shoppers willing to wait out the current chaos could end up getting a better deal.
I have been wondering what to do here myself. As a new dad, my family will need a new car seat early next year, and these plastic buckets, which generally must be bought new, don't come cheap—even under normal circumstances. For clues on how to navigate the dilemma of buying now or later, I have been collecting thoughts from experts in the online shopping industry.
One of the first lessons I learned doing this research was that if I decided to buy in advance, I wouldn't be alone. 'To some extent, we've seen some heightened buying in certain categories that may indicate stocking up in advance of any potential tariff impact,' Amazon CEO Andy Jassy said on an earnings call last week. eBay also said it saw signs of what could be prebuying, though it didn't specify which products people are stocking up on.
On the other hand, there are hints that most consumers have been holding out for now. This time of year tends to be relatively quiet for sales of iPhones and other Apple products, and that's been true to date in 2025, CEO Tim Cook said on the company's earning call last week. Mastercard's earning comments also said that shoppers were spending the expected amount. And Etsy even saw a drop in the total value of merchandise sold as customers held back on gifts and trinkets.
So if other consumers are a guide, I could go either way with my car seat purchase. What about prices? As the impact of tariffs started to hit last week, Amazon's Jassy said that prices on the platform hadn't surged 'appreciably' so far. He added that Amazon was 'maniacally focused' on keeping prices down. It helps that Amazon has a global network of competing suppliers and merchants. For example, if one seller raises prices, another may hold theirs steady to gain market share, Jassy said. 'Customers are going to have a better chance of finding variety on selection and on lower prices when they come here,' he added.
Jassy didn't touch on illicit tactics, including tariff evasion, that could keep the prices of imported products artificially low. But several ecommerce strategists who help companies sell products on Amazon tell WIRED that factories and distributors in Asia are admitting to new attempts to skirt tariffs, including by underdeclaring the value of shipments to US customs officials. 'It's always been an unfair playing field, and now they are pushing the envelope even more,' says Dave Bryant, cofounder of EcomCrew.
Amazon spokesperson Jessica Martin says sellers 'are required to follow all applicable laws and regulations when importing items for sale.'
The government losing out on tariff revenue isn't great, but name a shopper that's going to fret at the trade-off of more affordable prices, Bryant says. He and other strategists agree with Jassy that competitive items—think household goods or generic party favors—are unlikely to skyrocket in price on Amazon. More boutique offerings, though, could grow more expensive because of tariffs.
Some of those increases appear to be materializing. In mid-April, the average price of goods on Amazon was higher than the previous 90 days in nine out of 27 categories monitored by the price-tracking firm Keepa, according to a WIRED analysis. By this past Wednesday, the number of categories with higher prices shot up to 24. Industrial items, tools, and baby products experienced some of the biggest jumps, with average price increases of around 2.5 percent to 5 percent. More increases are coming later this month, including reportedly a bump of $20 or more for the Graco car seat that I have been eyeing.
The big question is how much worse will those increases get. The steepest tariffs—those on Chinese imports—could more than double the price of affected products. Normally, Amazon restricts sellers that make drastic price hikes. But it has been allowing for increases of about 10 percent a week in certain cases, roughly five times more than the previous limit, according to Jason Boyce, CEO and founder of ecommerce strategy company Avenue7Media. That means significant surges could come in days and weeks, not months, adding pressure on consumers like me to make decisions sooner rather than later.
Martin, the Amazon spokesperson, says prices have not changed outside of usual fluctuations and that the platform's pricing policy continues to apply.
The last factor at play in the when-to-buy dilemma is the chance of a resolution. If you trust the vibes that some big tech platforms are publicly expressing, there is some optimism in the air about averting crisis-level prices
Companies are buying online ads to market their products like it's 'mostly business as usual,' Reddit chief operating officer Jen Wong said on an earnings call last week. Typically, marketing budgets would be an early casualty for companies trying to cut expenses and keep their prices low. Wong's comments echoed those of executives from other leading online ad sellers, including Amazon, Google, Microsoft, and Meta. The positive outlook has been encouraging to Wall Street—the US stock market is trending up as if tariff-fueled price hikes aren't going to dissuade all of us from shopping in the coming months.
But Trump and the outcomes of negotiations between the US and its trading partners are unpredictable. 'Obviously, none of us knows exactly where tariffs will settle or when,' Amazon's Jassy said in his comments last week. CEOs and their chief financial officers have taken to calling this reality 'macroeconomic uncertainty.' The phrase has been uttered on 222 companies' earnings calls already this year, up from 178 in all of last year, according to a WIRED review of transcripts from financial data company AlphaStreet.
Some companies have been trying to create certainty when it comes to Trump and his trade policies since his first presidential term. Apple attempted to control its costs by shifting some of its manufacturing out of China, which has long been Trump's top target for tariffs. But this time around Trump has applied tariffs to every country imaginable, including an island inhabited solely by penguins.
Exemptions remain another hope for companies and their customers. Last week, baby monitor maker Nanit led a rally in New York City urging for a tariffs reprieve for baby products. This week, Trump and his treasury secretary both said they were considering it, though Trump added that he preferred not to have too many exemptions.
Nanit's Malaysia-made monitors—it abandoned China during Trump's first term— are subject to 10 percent tariffs at the moment. The levy could grow to 24 percent or more come July under the president's current plans. Nanit CEO, Anushka Salinas, says her goal is to avoid price increases as her company tries to grow its base of 1 million monthly users. It helps to have supportive investors who could step in with additional funding. The startup's subscription-based software, a business line that tends to have wider profit margins, also gives it some financial cushioning.
But the higher the tariffs go, the more challenging it will become to avoid a price increase. Salinas personally made the call to buy a bed for her 4-year-old sooner than she would have otherwise. I made a similar choice. A car seat I don't need until next year is arriving tomorrow. Better $200 now than $500 later.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Leach International Corporation Approves FDH Electronics Brand Stealth Aerospace as an Authorized Channel Partner for the Commercial Airline and MRO Markets
Commercial aviation industry to benefit from access to Leach's trusted product lines through a reliable, scaled and independent distribution partner FDH Electronics & Leach Aerospace OKLAHOMA CITY, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Oklahoma-based FDH Electronics, a unified FDH Aero division focused solely on serving the mil-aero market's electronic component needs, is pleased to announce that its aftermarket division, Stealth Aerospace, has been named as an approved distribution channel by Leach International Corporation to support commercial airline and MRO customers. This strategic partnership builds on the companies' long-standing relationship and reinforces their shared commitment to deliver best-in-class service, product availability and technical support to the commercial aviation aftermarket sector. Alon Glickstein, Vice President at FDH Electronics, commented: 'We are incredibly proud to have established this partnership with Leach International. Their long-standing reputation for high-reliability products fits perfectly with our mission at FDH Electronics — to provide our customers with exceptional service, technical support, and inventory availability that meets their evolving needs.' Leach International, a leading manufacturer of advanced electrical switches, relays, and power distribution components for the aerospace and defense markets, sees this partnership as a key step toward strengthening its presence in the aftermarket segment. Justin Coates, Vice President of Sales & Marketing at Leach International Corporation, added: 'This agreement with FDH Electronics' Stealth Aerospace division ensures that Leach's products will be supported with an incredibly high level of service. Their proven performance in the aerospace aftermarket gives us full confidence that customers will benefit from rapid access to inventory, technical insight, and dedicated aftermarket expertise.' This announcement marks a new chapter in aftermarket excellence and provides the commercial aviation industry with access to Leach's trusted product lines through a specialized and reliable distribution partner. About FDH ElectronicsFDH Electronics is a global one-stop shop with one of the most expansive inventory levels in the industry, built on FDH Aero's industry-leading supply chain solutions. It supplies a variety of interconnect, wire and cable, and electromechanical components for the aerospace, defense, and space markets. FDH Electronics is your go-to resource for value-added connectors, 1553 Data Bus interconnect products, custom harnesses, high-performance aerospace-grade wire and cable, and high-frequency RF connectors. When you need critical interconnect or electromechanical components, you can rely on FDH Electronics to deliver. To search by part number, please visit: Contact:Heather RosenowExecutive Vice President, Marketing & Communicationsmediarelations@ About Leach International CorporationLeach International Corporation has been a leader in aerospace switching and control technology since 1919. Leach designs and manufactures high-reliability relays, contactors, and power distribution systems for aerospace, defense, and industrial applications. Contact:relayed@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
Snap Stock Plunged After Earnings. Buy the Dip?
Key Points Sponsored Snaps are showing strong engagement and conversion gains. Subscription revenue from Snapchat+ is growing quickly from a small base. Heavy stock-based compensation and dilution keep valuation concerns high. 10 stocks we like better than Snap › Snap (NYSE: SNAP), the parent company of social media platform Snapchat, took a hard hit following its second‑quarter earnings release earlier this month. Shares tumbled, driven by worries about slowing growth, execution missteps, and a worsening net loss. But dig deeper, and the underlying narrative is more nuanced; there were a lot of positives in the report, too. Revenue and users continue to grow at a robust rate, free cash flow has turned positive year over year, and new ad formats, such as sponsored Snaps, are demonstrating real engagement traction. Given the mix of good and bad in its underlying business and the stock's recent sell-off, it makes sense to check whether the shares have been pushed into oversold territory. Let's look at what changed in the business and what it might mean for investors today. Momentum in key areas Snap reported second-quarter revenue of $1.345 billion, marking a 9% gain from a year earlier. Further, the lifeblood of the company -- user activity -- performed exceptionally well. Daily active users (DAUs) rose 9% to 469 million, while monthly active users (MAUs) climbed 7% to 932 million. Operating cash flow reached $88 million, and free cash flow came in positive at $24 million, a notable reversal from the previous year, when the company burned cash. Still, Snap posted a net loss of $263 million (wider than a net loss of $249 million in the year-ago quarter), and adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) slid lower on a year-over-year basis to $41 million, underscoring that profitability remains out of reach. An ad platform glitch -- where auction settings pushed some campaigns to clear at unusually low prices -- weighed on performance early in the quarter. Snap reversed the change mid-period, and management said that advertiser activity is of my favorite data points to support the bull case: On the diversification front, "other revenue" -- primarily from subscriptions like Snapchat+ -- grew 64% year over year, and Snapchat+ subscribers rose roughly 42%, nearing 16 million. One of the quarter's most promising developments was sponsored Snaps -- video ads delivered directly into users' inboxes. Snap co-founder Evan Spiegel said in the company's second-quarter earnings call that after a user opens a sponsored Snap from their chat feed, they "exhibit significantly higher engagement per full-screen ad view, driving a 2x increase in conversion, a 5x increase in click-to-convert ratios and a 2x increase in website dwell times compared to other inventories. That signals a powerful new lever for monetizing deeply engaged the company's fast-growing subscription business, advertising revenue growth trends after the glitch was addressed, and momentum in sponsored Snaps, management guided for continued top-line growth in Q3. Valuation remains a concern Despite a handful of promising trends at Snap, valuation remains troubling. The company has long leaned on equity dilution and stock-based compensation to fund growth. While Q2 did include a $243 million share repurchase (30 million shares), its stock-based compensation burden remains high. Full-year stock-based comp is still pegged north of $1.1 billion, even after recent downward revisions. Keep in mind that we're talking about a company with only a $12 billion market cap. Dilution continues to erode per-share value, even as Snap shows cash generation. So while the sell-off may feel overdone, the stock hasn't quite yet fallen low enough to make it a bargain. Of course, I could be wrong. A potential bull case lies not in near-term profits but in optionality -- whether Snap can scale newer revenue streams, stabilize pricing, and get to a point where it doesn't need to regularly materially dilute shareholders. Overall, Snap trades at a valuation that remains questionable given its history of dilution and heavy reliance on noncash compensation. But the emergence of fast-growing subscription revenue, sponsored Snaps, better cash flow, and an engaged user base make it extremely interesting -- worthy of a high spot on any investor's watchlist. Should you buy stock in Snap right now? Before you buy stock in Snap, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Snap wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Daniel Sparks and his clients have no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Snap Stock Plunged After Earnings. Buy the Dip? was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
25 minutes ago
- Yahoo
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool Sign in to access your portfolio